Thryv Therapeutics Initiates Phase 2/3 Trial for Long QT Syndrome Treatment, Receives FDA Fast Track Designation
核心洞察
Thryv Therapeutics (搜索) has commenced patient dosing in its Wave II Phase 2/3 clinical study evaluating THRV-1268 in patients with genetically confirmed Long QT Syndrome Type 2 (搜索).
The FDA granted Fast Track Designation to THRV-1268 for treating Long QT Syndrome Type 2 (搜索) and Type 3, facilitating expedited development and review.
THRV-1268 represents a potential first-in-class disease-modifying therapy targeting SGK1 (搜索) to address underlying QT interval prolongation in genetically defined LQTS populations.
Thryv Therapeutics (搜索) has achieved two significant milestones in developing THRV-1268, a novel serum glucocorticoid inducible kinase 1 (搜索) (SGK1 (搜索)) inhibitor for Long QT Syndrome (搜索) (LQTS). The clinical-stage biotechnology company announced that patient dosing has commenced in its Wave II Phase 2/3 clinical study for genetically confirmed LQTS Type 2, while simultaneously receiving FDA Fast Track Designation for the investigational therapy in LQTS Type 2 and Type 3.
Wave II Clinical Study Advances
The Wave II clinical study (NCT07277582) represents a multicenter Phase 2/3 trial enrolling patients with genetically confirmed Long QT Syndrome Type 2 (搜索). Professor Vasanth Vedantham at UCSF Health (搜索) in San Francisco initiated dosing for the first of fourteen patients planned in Part A of the study.
The primary endpoint will assess the safety and efficacy of two dose levels of THRV-1268 over a 12-week period, measured by change in QTcF over six hours, together with evaluations of cardiac rhythm stability, safety, and tolerability. Enrollment at leading inherited arrhythmia centers across the United States is advancing on track, with the company expecting to deliver initial data in the fourth quarter of 2026.
"The emerging clinical evidence for SGK1 (搜索)'s role in cardiac electrophysiology gives me hope that we may finally have a new approach to Long QT Syndrome (搜索) that addresses the underlying QT interval prolongation," said Vasanth Vedantham, Professor of Medicine and Cardiac Electrophysiologist at UCSF Health (搜索). "Initiating Wave II is a meaningful step forward for the potential treatment of patients living with Long QT Syndrome Type 2 (搜索). Patients and their families carry an enormous burden – not just the medical complexity of managing arrhythmic risk, but the emotional weight of living with a condition that remains life-threatening despite current therapies."
Treatment Protocol and Formulation Strategy
Participants in the Wave II study will initially receive THRV-1268 as an oral suspension for 12 weeks, a formulation selected to accelerate data collection for the pediatric population. Patients will have the option to transition to an adult tablet formulation and continue therapy for up to one year.
FDA Fast Track Designation Significance
The FDA's Fast Track Designation for THRV-1268 in LQTS Type 2 and Type 3 is intended to facilitate development and expedited review of investigational therapies addressing serious conditions with unmet medical needs. This designation enables more frequent interactions with the FDA and potential eligibility for Rolling Review, Priority Review, and Accelerated Approval if relevant criteria are met.
"Fast Track Designation represents a meaningful regulatory milestone that reflects the serious and underserved nature of genetically defined Long QT Syndrome (搜索)," said Amy Sehnert, Chief Medical Officer of Thryv Therapeutics (搜索). "This recognition by the FDA reinforces our confidence in THRV-1268 and its potential to become the first disease-modifying therapy to specifically target the underlying disease biology of Long QT Syndrome."
Precision Medicine Approach
Thryv Therapeutics (搜索) is pioneering a precision medicine approach to treating genetic arrhythmia syndromes and cardiometabolic diseases (搜索) through potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (搜索) (SGK1 (搜索)). The company's focus on SGK1 inhibition represents a novel therapeutic strategy targeting QTc reduction and arrhythmic risk in genetically defined LQTS populations.